Centocor Ortho Biotech Inc., Schering-Plough Corporation (JOBS) Two-Year Data Show Patients Receiving SIMPONI(TM) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

Bookmark and Share

COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) injections of SIMPONI(TM) (golimumab) 50 mg or 100 mg every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Investigators reported these new data from the long term treatment extensions of the GO-REVEAL and GO-RAISE trials at the 2009 European League Against Rheumatism (EULAR) Annual Congress.

Back to news